Clinical trials: Antibody
Multiple Myeloma
Assessing Free Immunoglobulin Light Chains in Patients With Myeloma
Multiple myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow. These plasma cells produce an abnormal protein called paraprotein / M spike in the serum which can be serially monitored to assess the…
- Trial name
- NCT00301275
- Where
- United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Previously Treated CD20+ B-cell Malignancies
Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies
Ocaratuzumab is a third-generation, fully humanized IgG1 monoclonal antibody (mAb) targeting the CD20 surface marker on normal and malignant B lymphocytes.
- Trial name
- NCT01858181
- Testing
- ocaratuzumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mentrik Biotech, LLC
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
The purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating ANCA-associated vasculitis.
- Trial name
- SCOUT (NCT02169219)
- Testing
- Glucocorticoids, Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Resectable Non-small Cell Lung Cancer, Bispecific Antibody
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
The advent of immunotherapy has changed the treatment landscape for patients with non-small cell lung cancer. It has become the mainstay of perioperative treatment for patients with resectable non-small cell lung cancer。…
- Conditions
- Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
- Trial name
- Neoadjuvant (NCT06946836)
- Testing
- AK104
- Volunteers
- 80 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Advanced Cancer, Metastatic Cancer
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.
- Trial name
- NCT02529553
- Testing
- LY3076226
- Where
- 4 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque Psoriasis
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- VIP-S (NCT02690701)
- Testing
- Secukinumab 300 mg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Vaccine Reaction
Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB)
Longitudinal study on healthy subjects to investigate the longevity of the antibody response to the Pfizer-BioNTech COVID-19 vaccine.
- Trial name
- SARS-AB (NCT05515081)
- Testing
- blood sample collection
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Camillo, Venezia, Italy
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02620865
- Testing
- Aldesleukin, Antibody Therapy, Fluorouracil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg
Paroxysmal Nocturnal Hemoglobinuria
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
- Trial name
- NCT06932471
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Rhinitis, Allergic, Asthma, Allergic
Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of…
- Conditions
- Rhinitis, Allergic, Asthma, Allergic, Conjunctivitis, Allergic, Atopic Dermatitis
- Trial name
- NCT06063044
- Where
- China
- Volunteers
- 407 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab…
- Trial name
- START-002 (NCT06827613)
- Testing
- STAR0602, Sacituzumab Govitecan (SG)
- Where
- 8 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Marengo Therapeutics, Inc.
Hepatitis B Infection
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
- Trial name
- NCT03519113
- Testing
- GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Green Cross Corporation
HIV Infections, Yellow Fever Vaccine
"Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients"
Participating countries: Belgium Context: In June 2013, WHO notified that "a single dose of YF vaccine is sufficient to confer sustained life-long protective immunity against YF disease and that a booster dose is not necessary".
- Trial name
- NCT03591003
- Testing
- Yellow fever neutralizing antibodies measure
- Where
- 12 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Metastatic Melanoma
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
- Trial name
- NCT01055522
- Testing
- Arm 1: L19IL2 + Dacarbazine, Arm 3: Dacarbazine, ARM 2: L19IL2 + Dacarbazine
- Where
- 10 sites in Austria, Germany and 2 more
- Volunteers
- 102 people
- Sponsor
- Philogen S.p.A.
Alzheimer Disease, Cognitive Dysfunction
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Dementia
- Trial name
- Autonomy (NCT04619420)
- Testing
- JNJ-63733657
- Where
- 122 sites in United States, Australia and 8 more
- Volunteers
- 523 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B
This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 12-13 years who were vaccinated with four doses of Infanrix™-Hexa in infancy and to assess the anamnestic response…
- Trial name
- NCT02052661
- Testing
- Engerix™-B Kinder
- Where
- 11 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Salivary Gland Cancer
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
(1) To apply Bayesian statistics to screen for the most effective treatment regimen containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) for locally advanced or…
- Trial name
- NCT05898373
- Testing
- vedicitumomab (Edisil, RC48）, vedicitumomab in combination with pyrrolizidine, RC48 in combination with a platinum-based chemotherapeutic agent
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00007956
- Testing
- monoclonal antibody mono-dgA-RFB4
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.